Evidence map›Paper›PMID 34153623›Full record

ArticleEpidemics2021

Lessons for preparedness and reasons for concern from the early COVID-19 epidemic in Iran.

Mahan Ghafari, Bardia Hejazi, Arman Karshenas, Stefan Dascalu, Alireza Kadvidar, Mohammad A Khosravi, Maryam Abbasalipour, Majid Heydari, Sirous Zeinali, Luca Ferretti and 2 more

Abstract read
In one paragraph

Article in Epidemics, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Estimating SARS-CoV-2 variant fitness and the impact of interventions in England using statistical and geo-spatial agent-based models.Philosophical transactions. Series A, Mathematical, physical, and engineering sciences · 2022
    Article
  8. Article
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Mahan GhafariDepartment of Zoology, Peter Medawar Building for Pathogen Research, University of Oxford, Oxford, UK. Electronic address: mahan.ghafari@zoo.ox.ac.uk.
Bardia HejaziDepartment of Physics, Wesleyan University, Middletown, CT, USA.
Arman KarshenasDepartment of Engineering, University of Oxford, Oxford, UK.
Stefan DascaluDepartment of Zoology, Peter Medawar Building for Pathogen Research, University of Oxford, Oxford, UK; Avian Influenza Virus, The Pirbright Institute, Woking, UK.
Alireza KadvidarCenter for Statistical and Operational Research, Statsminute Company, Tehran, Iran.
Mohammad A KhosraviKawsar Human Genetic Research Center, Kawsar Biotech Company, Tehran, Iran.
Maryam AbbasalipourKawsar Human Genetic Research Center, Kawsar Biotech Company, Tehran, Iran.
Majid HeydariEditorial Board, Donya-e-Eqtesad Daily Newspaper, Tehran, Iran.
Sirous ZeinaliKawsar Human Genetic Research Center, Kawsar Biotech Company, Tehran, Iran; Department of Molecular Medicine, Biotechnology Research Center, Pasteur Institute of Iran, Tehran, Iran.
Luca FerrettiBig Data Institute, Li Ka Shing Centre for Health Information and Discovery, University of Oxford, Oxford, UK.
Alice LeddaDepartment of Infectious Disease Epidemiology, Imperial College London, UK.
Aris KatzourakisDepartment of Zoology, Peter Medawar Building for Pathogen Research, University of Oxford, Oxford, UK. Electronic address: aris.katzourakis@zoo.ox.ac.uk.

Funding

Biotechnology and Biological Sciences Research Council BB/M011224/1
6 · The paper itself

Abstract

introductionMany countries with an early outbreak of SARS-CoV-2 struggled to gauge the size and start date of the epidemic mainly due to limited testing capacities and a large proportion of undetected asymptomatic and mild infections. Iran was among the first countries with a major outbreak outside China.

methodsWe constructed a globally representative sample of 802 genomes, including 46 samples from patients inside or with a travel history to Iran. We then performed a phylogenetic analysis to identify clades related to samples from Iran and estimated the start of the epidemic and early doubling times in cases. We leveraged air travel data from 36 exported cases of COVID-19 to estimate the point-prevalence and the basic reproductive number across the country. We also analysed the province-level all-cause mortality data during winter and spring 2020 to estimate under-reporting of COVID-19-related deaths. Finally, we use this information in an SEIR model to reconstruct the early outbreak dynamics and assess the effectiveness of intervention measures in Iran.

resultsBy identifying the most basal clade that contained genomes from Iran, our phylogenetic analysis showed that the age of the root is placed on 2019-12-21 (95 % HPD: 2019-09-07 - 2020-02-14). This date coincides with our estimated epidemic start date on 2019-12-25 (95 %CI: 2019-12-11 - 2020-02-24) based air travel data from exported cases with an early doubling time of 4.0 (95 %CI: 1.4-6.7) days in cases. Our analysis of all-cause mortality showed 21.9 (95 % CI: 16.7-27.2) thousand excess deaths by the end of summer. Our model forecasted the second epidemic peak and suggested that by 2020-08-31 a total of 15.0 (95 %CI: 4.9-25.0) million individuals recovered from the disease across the country.

conclusionThese findings have profound implications for assessing the stage of the epidemic in Iran despite significant levels of under-reporting. Moreover, the results shed light on the dynamics of SARS-CoV-2 transmissions in Iran and central Asia. They also suggest that in the absence of border screening, there is a high risk of introduction from travellers from areas with active outbreaks. Finally, they show both that well-informed epidemic models are able to forecast episodes of resurgence following a relaxation of interventions, and that NPIs are key to controlling ongoing epidemics.

Indexed as

COVID-19EpidemicsHumansIranPhylogenySARS-CoV-2COVID-19Excess mortalityNon-pharmaceutical interventions (NPIs)PhylogeneticsSEIR modellingUnder-reporting

Identifiers

PMID34153623
PMCPMC8163697

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.